GAITHERSBURG, Md., Aug. 15 /PRNewswire/ -- Emergent BioSolutions Inc. announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission related to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.
J.P. Morgan Securities Inc. will serve as sole book-running manager for the offering. Cowen and Company, LLC will be the joint lead manager, and HSBC Securities (USA) Inc. will be the co-manager for the offering.
Emergent BioSolutions is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. The Company operates in two business segments: biodefense and commercial. In its biodefense business, Emergent BioSolutions develops and commercializes immunobiotics for use against biological agents that are potential weapons of bioterrorism. The Company manufactures and markets BioThrax®, also referred to as anthrax vaccine adsorbed, the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. In its commercial business, Emergent BioSolutions develops immunobiotics for use against infectious diseases with significant unmet or underserved medical needs.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.
When available, copies of the preliminary prospectus relating to this offering may be obtained by contacting J.P. Morgan Securities Inc., 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245.
Source: Emergent BioSolutions Inc.
